A united risk model of 11 immune‑related gene pairs and clinical stage for prediction of overall survival in clear cell renal cell carcinoma patients

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–387.
   PubMed Web of Science ®Google Scholar
• Hao H, Wang Z, Ren S, et al. Reduced GRAMD1C expression correlates to poor prognosis and immune infiltrates in kidney renal clear cell carcinoma. PeerJ. 2019;7:e8205.
   PubMed Web of Science ®Google Scholar
• Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part A: renal, Penile, and testicular tumours. Eur Urol. 2016;70(1):93–105.
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810.
   PubMed Web of Science ®Google Scholar
• Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–1132.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang J, Hong B, et al. Gene signatures and prognostic values of m6A regulators in clear cell renal cell carcinoma - a retrospective study using TCGA database. Aging (Albany NY). 2019;11(6):1633–1647.
   PubMedGoogle Scholar
• Breau RH, Cagiannos I, Knoll G, et al. Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol. BMJ Open. 2019;9(1):e025662.
   PubMedGoogle Scholar
• Li W, Zeng J, Luo B, et al. [High expression of activated CD4(+) memory T cells and CD8(+) T cells and low expression of M0 macrophage are associated with better clinical prognosis in bladder cancer patients]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2020;36:97–103.
   PubMedGoogle Scholar
• Jingushi K, Uemura M, Nakano K, et al. Leukocyte‑associated immunoglobulin‑like receptor 1 promotes tumorigenesis in RCC. Oncol Rep. 2019;41:1293–1303.
   PubMed Web of Science ®Google Scholar
• Karner C, Kew K, Wakefield V, et al. Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis. BMJ Open. 2019;9(3):e024691.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Sima P, Vannucci L, Vetvicka V. Immunity in cancer and atherosclerosis. Ann Transl Med. 2019;7(9):204.
   PubMed Web of Science ®Google Scholar
• Refolo MG, Lotesoriere C, Messa C, et al. Integrated immune gene expression signature and molecular classification in gastric cancer: new insights. J Leukoc Biol. 2020;108(2):633–646.
   PubMed Web of Science ®Google Scholar
• Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19–20):1267–1284.
   PubMed Web of Science ®Google Scholar
• Zou Y, Hu C. A 14 immune-related gene signature predicts clinical outcomes of kidney renal clear cell carcinoma. PeerJ. 2020;8:e10183.
   PubMed Web of Science ®Google Scholar
• Zhou X, Qiu S, Jin D, et al. Development and validation of an individualized immune-Related gene Pairs prognostic signature in papillary renal cell carcinoma. Front Genet. 2020;11:569884.
   PubMed Web of Science ®Google Scholar
• Wan B, Liu B, Huang Y, et al. Prognostic value of immune-related genes in clear cell renal cell carcinoma. Aging (Albany NY). 2019;11(23):11474–11489.
   PubMedGoogle Scholar
• Leek JT, Scharpf RB, Bravo HC, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet. 2010;11(10):733–739.
   PubMed Web of Science ®Google Scholar
• Heinäniemi M, Nykter M, Kramer R, et al. Gene-pair expression signatures reveal lineage control. Nat Methods. 2013;10(6):577–583.
   PubMed Web of Science ®Google Scholar
• Li B, Cui Y, Diehn M, et al. Development and validation of an individualized immune prognostic signature in early-Stage nonsquamous Non-Small cell lung cancer. JAMA Oncol. 2017;3(11):1529–1537.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhao Y, Zhang J, et al. Development and validation of an immune-related gene pairs signature in colorectal cancer. Oncoimmunology. 2019;8(7):1596715.
   PubMed Web of Science ®Google Scholar
• Wang Z, Song Q, Yang Z, et al. Construction of immune-related risk signature for renal papillary cell carcinoma. Cancer Med. 2019;8(1):289–304.
   PubMed Web of Science ®Google Scholar
• Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337–344.
   PubMed Web of Science ®Google Scholar
• Huang C, Zhao J, Zhu Z. Prognostic nomogram of prognosis-Related genes and clinicopathological characteristics to predict the 5-Year survival rate of colon cancer patients. Front Surg. 2021;8:681721.
   PubMed Web of Science ®Google Scholar
• Lee YY, Kim TJ, Kim JY, et al. Genetic profiling to predict recurrence of early cervical cancer. Gynecol Oncol. 2013;131(3):650–654.
   PubMed Web of Science ®Google Scholar
• Liu X, Wu S, Yang Y, et al. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer. Biomed Pharmacothe. 2017;95:55–61.
   PubMed Web of Science ®Google Scholar
• Lobo J, Barros-Silva D, Henrique R, et al. The emerging role of epitranscriptomics in cancer: focus on urological tumors. In: Genes. 2018. p. 9. Multidisciplinary Digital Publishing Institute (MDPI).
   Google Scholar
• Shibata T, Lieblong BJ, Sasagawa T, et al. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treat Rev. 2019;78:8–16.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhao Y, Tu Q, et al. The role of programmed cell death ligand-1/ programmed cell death-1 (PD-L1/PD-1) in HPV-induced cervical cancer and potential for their use in blockade therapy. Curr Med Chem. 2020;28:893–909.
   Web of Science ®Google Scholar
• Zhou C, Tuong ZK, Frazer IH. Papillomavirus immune evasion strategies target the infected cell and the local immune system. Front Oncol. 2019;9:682.
   PubMed Web of Science ®Google Scholar
• Li F, Guo P, Dong K, et al. Identification of key biomarkers and potential molecular mechanisms in renal cell carcinoma by bioinformatics analysis. J Comput Biol. 2019;26(11):1278–1295.
   PubMed Web of Science ®Google Scholar
• Yang Y, Long X, Li G, et al. Prediction of clinical prognosis in cutaneous melanoma using an immune-related gene pair signature. Bioengineered. 2021;12(1):1803–1812.
   PubMed Web of Science ®Google Scholar
• Peng PL, Zhou XY, Yi GD, et al. Identification of a novel gene pairs signature in the prognosis of gastric cancer. Cancer Med. 2018;7(2):344–350.
   PubMed Web of Science ®Google Scholar
• Feng JF, Liu JS, Huang Y. Lymphopenia predicts poor prognosis in patients with esophageal squamous cell carcinoma. Medicine (Baltimore). 2014;93(27):e257.
   PubMed Web of Science ®Google Scholar
• Hoffmann TK, Dworacki G, Tsukihiro T, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res off J Am Assoc Cancer Res. 2002;8:2553–2562.
   PubMed Web of Science ®Google Scholar
• Saroha S, Uzzo RG, Plimack ER, et al. Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol. 2013;189(2):454–461.
   PubMed Web of Science ®Google Scholar
• Finotello F, Trajanoski Z. New strategies for cancer immunotherapy: targeting regulatory T cells. Genome Med. 2017;9(1):10.
   PubMedGoogle Scholar
• Long J, Wang A, Bai Y, et al. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine. 2019;42:363–374.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–444.
   PubMed Web of Science ®Google Scholar
• Hutterer GC, Pichler M, Chromecki TF, et al. Tumour-associated macrophages might represent a favourable prognostic indicator in patients with papillary renal cell carcinoma. Histopathology. 2013;63(3):309–315.
   PubMed Web of Science ®Google Scholar
• Tamma R, Rutigliano M, Lucarelli G, et al. Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment. Urol Oncol. 2019;37(6):355.e11-.e19.
   PubMed Web of Science ®Google Scholar